Founder of Eucrates Biomedical Acquisition Corp., Daphne Karydas currently is Chief Operating & Financial Officer of Flare Therapeutics, Inc.

She is also on the board of Elicio Therapeutics, Inc., LogicBio Therapeutics, Inc. and Eucrates Biomedical Acquisition Corp.

Ms. Karydas previously held the position of Chief Financial Officer of Syndax Pharmaceuticals, Inc., Project Chemical Engineer at Merck & Co., Inc., Vice President at Goldman Sachs Asset Management LP, Senior VP-Corporate Financial Planning & Analysis at Allergan Ltd. (Ireland), Portfolio Manager & Senior Analyst at The Boston Company Asset Management LLC, Vice President of BNY Mellon Investment Adviser, Inc., Executive Director at JPMorgan Investment Management, Inc. and Associate for Goldman Sachs & Co. LLC.

Ms. Karydas received an undergraduate degree and a graduate degree from Massachusetts Institute of Technology and an MBA from Harvard Business School.